Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single ascending dose placebo-controlled study of REC-4881 in healthy volunteers
NL-OMON51761Active, not recruiting
- Sponsor
- Recursion Pharmaceuticals
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of TAK-733 in colon cancer and hereditary colorectal cancer (4 arms), sponsored by Recursion Pharmaceuticals. Primary endpoint: Safety and tolerability of single ascending doses of REC-4881. Started Feb 2022; status: active, not recruiting.
02
Drugs
TAK-733
03
Conditions
colon cancerhereditary colorectal cancer
Beyond the preview
Go deeper on NL-OMON51761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51761.